While bortezomib treatment slightly affected the ratio of CD38+/CD138Bright MM cells, it failed to induce apoptosis on myeloma cells with 8p21 deletion, either alone or in combination with soluble TRAIL/APO2L (Fig 4B and 4C). This evidence concerns the gene CD38 and plasma cell myeloma.